Drug Discovery and Development
- All
- Analytical Services
- Bioanalytical Services
- Bioassay Development
- Biologics, Proteins, Vaccines
- Biosimilars
- Chemistry
- Clinical Trials
- Drug Delivery
- Drug Development
- Drug Discovery
- Formulation Development
- Information Technology
- Laboratory Testing
- Methods Development
- Microbiology
- Preclinical Outsourcing
- R&D
- Toxicology
-
Bio News | Breaking News | Collaborations & Alliances | Industry News | Information Technology
MasterControl and Elemental Machines Form Biomanufacturing Partnership
Goal is to transform biomanufacturing by unifying digital production and Internet of Things (IoT) data and insights.06.24.22
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine
Program aimed to deliver early-stage clinical supply of plasmid DNA for drug substance manufacturing.06.24.22
-
Breaking News | Collaborations & Alliances | Drug Discovery
Cullinan Oncology, Taiho to Develop & Commercialize CLN-081/TAS6417 in the U.S.
Will equally share future profits in the U.S.06.23.22
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
BioNTech Breaks Ground on First mRNA Vax Mfg. Facility in Africa
Facility will be initially equipped with two BioNTainers, and is expected to employ about 100 staff by 2024.06.23.22
-
Clinical Trial Materials | Drug Delivery | Formulation Development | Vials
Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment
DWK Life Sciences offers a broad range of high-quality tubular glass CCS designed to ensure secure storage, safe delivery, and content integrity.
-
Biologics, Proteins, Vaccines | Breaking News | Trials & Filings
FDA Approves Merck’s Vaxneuvance in Infants and Children
Becomes the first pneumococcal conjugate vaccine approved in almost a decade to help protect pediatric populations.06.22.22
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Drug Development | Industry News
Galapagos to Acquire CellPoint and AboundBio
Gains scalable, decentralized and automated point-of-care cell therapy supply model and next-gen fully human antibody-based therapeutics platform.06.22.22
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
New Agreement Paves Way for Development of First African-owned COVID-19 Vaccine
Afrigen and Univercells enter a new agreement to develop the first African-own COVID-19 vaccine.06.21.22
-
Bio News | Bioanalytical Services | Breaking News | Collaborations & Alliances | CRO News | Industry News
Waters and BioInfra Establish the ASEAN Academy for Bioanalysis
Companies collaborate to promote development of bioanalytical skills with joint opening of the ASEAN Academy for Bioanalysis in South Korea.06.21.22
-
Breaking News | Drug Development | Trials & Filings
Abbvie’s SKYRIZI FDA-Approved as First IL-23 to Treat Crohn's Disease
As early as week 4, clinical response and clinical remission were achieved by significantly more subjects treated with SKYRIZI versus placebo.06.20.22
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development
Pfizer to Invest $95 Million in Valneva
Funds will further support the strategic Lyme partnership between the two companies.06.20.22
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News
BioCina Opens New GMP Plasmid DNA Manufacturing Suite
Equipped with up to 300 L single use fermentation capacity and suitably scaled downstream processing equipment.06.17.22
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News
Avid Bioservices and CRB Partner on Viral Vector Facility
53,000-square-foot facility addresses demands of commercial-scale viral vector production.06.17.22
-
Drug Development | GMPs/GCPs | Regulatory Affairs
Why is Big Pharma Increasingly Adopting 505(b)(2)?
USFDA 505(b)(2) pathway submissions (“(b)(2)s”) can be advantageous because they offer the potential for the accelerated approval of patient-centric medicines.
-
Breaking News | Drug Development | Drug Discovery | Industry News | Information Technology
OSE Immunotherapeutics, Microsoft Enter Research and Technology Collaboration
OSE to further develop its digital tools in AI and algorithmic approaches for the development of first-in-class immunotherapies.06.16.22
-
Biologics, Proteins, Vaccines | Cold Chain Management | Injectables | Parenterals
How to Improve the Cold Chain System in Remote Locations
Practical options for getting temperature-sensitive products to less-developed and harder-to-reach areas around the world.Online Exclusives Emily Newton, Contributing Writer 06.15.22
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News
Exothera Enters Industrial Scale AAV Manufacturing Collaboration
With partners LogicBio and Polyplus, the project aims to demonstrate the scalability and reproducibility of Exothera's AAV production processes.06.15.22
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News | R&D
Batavia Biosciences Expands HQ and R&D Services
Increases capacity for viral vectors and vaccine R&D in Netherlands.06.15.22
-
Breaking News | Drug Development | Facilities
Piramal Pharma Solutions Expands API Capabilities in India
Implements new tools to unlock Active Pharmaceutical Ingredient manufacturing capacity and support client needs in drug development and on-patent projects.06.14.22
-
Breaking News | Drug Development | Trials & Filings
Lilly's Olumiant Becomes First FDA-approved Treatment for Alopecia Areata
Approval based on Lilly's BRAVE-AA1 and BRAVE-AA2 trials, the largest Phase 3 clinical trial program in Alopecia Areata to date.06.14.22
